Role of farnesyltransferase inhibitors in hematologic malignancies

Expert Review of Anticancer Therapy

Volumn 4, Issue 5, 2004, Pages 843-856

  Santos, Edgardo S ^a   Rosenblatt, Joseph D ^a   Goodman, Mark ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

BMS 214662; Farnesyltransferase inhibitor; Lonafarnib; Mitogen activated protein kinase; Myelodysplasia; Myelofibrosis; Myeloid leukemia; Ras mutation; RhoB protein; Tipifarnib

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 5 [N [5 (2 BENZOXAZOLYL) 1 METHYL 2 [3,4 (METHYLENEDIOXY)PHENYL] 4 PENTENYL] N (2 NAPHTHYLMETHYL)CARBAMOYL] 1,3 DIOXOLANE 2,2,4 TRICARBOXYLIC ACID; ANTINEOPLASTIC AGENT; BMS 184467; BMS 185878; BMS 186511; CYCLOPHOSPHAMIDE; FLUOROURACIL; FTI 2153; GEMTUZUMAB OZOGAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; JANUS KINASE; L 731735; L 778123; LONAFARNIB; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RETINOIC ACID; RPR 115135; STAT3 PROTEIN; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ATAXIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RISK; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG FATALITY; DRUG TARGETING; FATIGUE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY DYSFUNCTION; LEUKEMIA; MULTIPLE MYELOMA; MYELODYSPLASIA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROTOXICITY; PATHOGENESIS; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; REVIEW; SIGNAL TRANSDUCTION; SUPRAVENTRICULAR TACHYCARDIA;

EID: 5444251026     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.5.843     Document Type: Review

References (87)

1. Lowenberg B, Downing JR, Burnett A. Medical progress: acute myeloid leukemia. N. Engl. J. Med. 341(14), 1051-1062 (1999).
2. Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol. 21(24), 4642-4649 (2003).
3. Rowe JM, Neuberg D, Friedenberg W et al. A Phase III study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Co-operative Oncology Group. Blood 103(2), 479-485 (2004).
4. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute leukemia. N. Engl. J. Med. 331(14), 896-903 (1994).
5. Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med. 339(23), 1649-1656 (1998).
6. Huang ME, Ye YC, Chen SR et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin. Med. J. (Engl.) 100(12), 949-953 (1987).
7. Warrell RP, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N. Engl. J. Med. 329(3), 177-189 (1993).
8. Fenaux P, Chastang C, Chevret S et al. A Randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 94(4), 1192-1200 (1999).
9. Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19(13), 3244-3254 (2001).
10. Prendergast GC. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr. Opin. Cell Biol. 12(2), 166-173 (2000).
11. Karp JE, Lancet JE, Kaufmann SH et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase I clinical laboratory correlative trial. Blood 97(11), 3361-3369 (2001).
12. Liesveld JL, Lancet JE, Rosell KE et al. Effects of the farnesyl transferase inhibitor R11577 on normal and leukemic hematopoiesis. Leukemia 17(9), 1806-1812 (2003).
13. Haluska P, Dy GK, Adjei AA. Farnesyl transferase inhibitors as anticancer agents. Eur. J. Cancer 38(13), 1685-1700 (2002).
14. Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW. Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol. 13(6), 470-476 (2001).
15. Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev. 17(3), 123-129 (2003).
16. Baum C, Kirschmeier P. Preclinical and clinical evaluation of farnesyltransferase inhibitors. Curr. Oncol. Rep. 5(2), 99-107 (2003).
17. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyl-transferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17(11), 3631-3652 (1999).
18. Sinensky M, Lutz RJ. The prenylation of proteins. Bioessays 14(1), 25-31 (1992).
19. Prendergast GC, Oliff A. Farnesyltransferase inhibitors: antineoplastic properties, mechanism of action, and clinical prospects. Semin. Cancer Biol. 10(6), 443-452 (2000).
20. Ashar HR, James L, Gray K et al. Farnesyl transferase inhibitors block farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem. 275(39), 30451-30457 (2000).
21. Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc. Natl Acad. Sci. USA 86(21), 8323-8327 (1989).
22. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors alter prenylation and growth-stimulating function of RhoB. J. Biol. Chem. 272(25), 15591-15594 (1997).
23. Prendergast GC. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology. Histol. Histopathol. 16(1), 269-275 (2001).
24. Sebti SM, Der CJ. Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nature Rev. Cancer 3(12), 945-951 (2003).
25. Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15 (11), 1283-1288 (1997).
26. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16(11), 1467-1473 (1998).
27. Yonemoto M, Satoh T, Arakawa H et al. J-104 871, a novel in a farnesyl pyrophosphate-competitive manner. Mol. Pharmacol. 54(1), 1-7 (1998).
28. 1 arrest only in serum starved cells. Int. J. Oncol. 18(4), 855-862 (2001).
29. Patnaik A, Rowinsky EK. Early clinical experience with farnesyl protein transferase inhibitors: from the bench to the bedside. In: Farnesyltransferase Inhibitors in Cancer Therapy. Setbi SM, Hamilton AD (Eds), Humana Press, NJ, USA, 233-249 (2001).
30. Britten CD, Rowinsky EK, Soignet S et al. A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778 123 in patients with solid malignancies. Clin. Cancer Res. 7(12), 3894-3903 (2001).
31. Manne V, Yan N, Carboni JM et al. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene 10(9), 1763-1779 (1995).
32. James GL, Goldstein JL, Brown MS. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 270(11), 6221-6226 (1995).
33. End DW, Smets G, Todd AV et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61(1), 131-137 (2001).
34. Lancet JE, Liesveld JL, Ludlow J et al. Effects of farnesyl transferase inhibitor R115777 on hematopoiesis, leukemic cell proliferation, and signaling through the mitogen-activated protein kinase (MAPK) pathway. Blood 94(10),149b (1999) (Abstract 3835).
35. Liu M, Bryant MS, Chen J et al. Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 58(21), 4947-4956 (1998).
36. Peters DG, Hoover RR, Gerlach MJ et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97(5), 1404-1412 (2001).
37. Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 97(5), 1399-1403 (2001).
38. Rose WC, Lee FY, Fairchild CR et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 61(20), 7507-7517 (2001).
39. Ranganathan S, McCauley RA, Hudes GR. Combined cell cycle and cytotoxic effects of paclitaxel and R115777, a specific inhibitor of p21 ras function and protein farnesylation in human prostate and breast carcinoma cell lines. Proc. Am. Assoc. Cancer Res. 40 (1999) (Abstract 3448).
40. Sonnichsen D, Damle B, Manning J et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of the farnesotransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 19 (2000) (Abstract 691).
41. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10(4), 147-154 (2000).
42. Cox AD, Der CJ. Farnesyltransferase inhibitors: promises and realities. Curr. Opin. Pharmacol. 2(4), 388-393 (2002).
43. Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochem. Biophys. Acta 1333(1), F51-F71 (1997).
44. Prendergast GC, Rane N. Farnesyltransferase inhibitors: mechanism and applications. Expert Opin. Investig. Drugs 10(12), 2105-2116 (2001).
45. Prendergast GC, Du W. Targeting farnesyltransferase: is Ras relevant? Drug Resist. Update 2(2), 81-84 (1999).
46. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell Biol. 19(3), 1831-1840 (1999).
47. Liu A, Prendergast GC. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. FEBS Lett. 481(3), 205-208 (2000).
48. Jiang K, Coppola D, Crespo NC et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell Biol. 20(1), 139-148 (2000).
49. Adini I, Rabinovitz I, Sun JF et al. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev. 17(21), 2721-2732 (2003).
50. Chen Z, Sun J, Pradines A, Favre G, Adriatic J, Sebti SM. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 275(24), 17974-17978 (2000).
51. Falugi C, Trombino S, Granone P, Margaritora S, Russo P. Increasing complexity of farnesyltransferase inhibitor activity: role in chromosome instability. Curr. Cancer Drug Targets 3(2), 109-118 (2003).
52. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J. Biol. Chem. 276(19), 16161-16167 (2001).
53. Skorski T, Bellacosa A, Nieborowska-Skorska M et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI3k/Akt dependent pathway. EMBO J. 16(20), 6151-6161 (1997).
54. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAPK kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77(6), 841-852 (1994).
55. Mansour SJ, Matten WT, Hermann AS et al. Transformation of mammalian cells by constitutively active MAPK kinase. Science 265(5174), 966-970 (1994).
56. Bennett AM, Tonks NK. Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science 278(5341), 1288-1291 (1997).
57. Whalen AM, Galasinski SC, Shapiro PS, Nahreini TS, Ahn NG. Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol. Cell Biol. 17(4), 1947-1958 (1997).
58. Raponi M, Belly R. Atkins D et al. Pharmacogenomic analysis reveals signaling pathway modulated by R115777 (Zarnestra) in acute myeloid leukemia. Proc. Am. Soc. Clin. Oncol. 21, 265a (2002) (Abstract 1057).
59. Schnittger S, Schoch C, Dugas M et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100(1), 59-66 (2002).
60. Stirewalt DL, Kopecky KJ, Meshinchi S et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97(11), 3589-3595 (2001).
61. Mizuki M, Fenski R, Halfter H et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96(12), 3907-3914 (2000).
62. Hayakawa F, Towatari M, Kiyoi H et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAPK and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19(5), 624-631 (2000).
63. Adjei AA, Erlichman C, Davis JN et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 60(7), 1871-1877 (2000).
64. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res. 6(6), 2318-2325 (2000).
65. Adnane J, Bizouarn FA, Chen Z et al. Inhibition of farnesyltransferase increases TGF-β Type II receptor expression and enhances the responsiveness of human cancer cells to TGF-β. Oncogene 19(48), 5525-5533 (2000).
66. Alcock RA, Dey S, Chendil D et al. Farnesyltransferase inhibitor (L-744,832) restores TGF-β Type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cell line MIA PaCa-2. Oncogene 21(51), 7883-7890 (2002).
67. Medeiros BC, Landau HA, Morrow MC, Eckhardt SG. The farnesyl transferase inhibitor zarnestra (R115777) exhibits a dual mechanism of action against P-glycoprotein overexpressing leukemia cell lines. Blood 102, 610a (2003) (Abstract 2250).
68. Gotlib J, Loh M, Vattikuti S et al. Phase I/II study of Zarnestra (farnesyltransferase inhibitor [FTI] R115777, tipifarnib) in patients with myeloproliferative disorders (MPDs): preliminary results. Blood 100, 798a (2002) (Abstract 3153). '
69. Cortes J, Albitar M, Thomas D et al. Efficacy of the farnesyl transferase R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101(5), 1692-1697 (2003).
70. Kurzrock R, Kantarjian HM, Cortes JE et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the Phase I setting. Blood 102(13), 4527-4534 (2003).
71. Cortes J, Kurzrock R, O'Brien SM et al. Phase I Study of a farnesyl transferase inhibitor (FTI), BMS-214662, in patients with refractory or relapsed acute leukemias. Blood 98, 594a (2001) (Abstract 2489).
72. List AF, DeAngelo D, O'Brien S et al. Phase I study of continuous oral administration of lonafarnib (Sarasar) in patients with advanced hematologic malignancies. Blood 100, 789a (2002) (Abstract 3120).
73. Ravoet C, Mineur P, Robin V et al. Phase I-II study of farnesyl transferase inhibitor (FTI), SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML). Blood 100, 794a (2002) (Abstract 3136).
74. Harousseau J-L, Reiffers J, Lowenberg B et al. Zarnestra (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter Phase II study. Blood 102, 176a. (2003) (Abstract 614).
75. Kurzrock R, Albitar M, Cortes JE et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 22(7), 1287-1292 (2004).
76. Lancet JE, Gojo I, Gotlib J et al. Tipifarnib (Zarnestra) in previously untreated poor-risk AML and MDS: interim results of a Phase II trial. Blood 102, 176a. (2003) (Abstract 613).
77. Gotlib J, Loh M, Lancet JE et al. Phase I/II study of tipifarnib (Zarnestra, farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders (MPDs): interim results. Blood 102, 921a (2003) (Abstract 3425).
78. Morgan MA, Sebil T, Ganser A, Reuter CWM. Potent inhibition of multiple myeloma cell migration by lovastatin. Blood 102, 443a (2003) (Abstract 1618).
79. Ochiai N, Yamada N, Uchida R et al. Incadronate augments the inhibitory effect of farnesyl transferase inhibitor R115777 (Zarnestra) on the growth of fresh and cloned myeloma cells in vitro. Blood 102, 689a (2003) (Abstract 2552).
80. Le Gouill S, Pellat-Deceunynck C, Harousseau JL et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 16(9), 1664-1667 (2002).
81. Alsina M, Fonseca R, Wilson EF et al. Farnesyltransferase inhibitor tipifarnib is well-tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103(9), 3271-3277 (2004).
82. Cortes J, Holyoake TL Saver RT et al. Continuous oral lonafarnib (Sarasar) for the treatment of patients with advanced hematologic malignancies: a Phase II study. Blood 100, 793a (2002) (Abstract 3132).
83. Feldman EJ, Cones J, Holyoake TL et al. Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome. Blood 102, 421a (2003) (Abstract 1531).
84. Cortes J, Garcia-Manero G, O'Brien S et al. Phase I study of a imatinib and tipifarnib (Zarnestra, R115777) in patients with chronic myeloid leukemia in chronic phase refractory to imatinib. Blood 102, 909a (2003) (Abstract 3383).
85. Gotlib J, Mauro M, O'Dwyer ME et al. Tipifarnib (Zarnestra) and imatinib (Gleevec) combination therapy in patients with advanced chronic myelogenous leukemia (CML): preliminary results of a Phase I study. Blood 102, 909a (2003) (Abstract 3384).
86. Cortes J, O'Brien S, Ferrajoli A et al. Phase I study of imatinib and lonafarnib (SCH66336) in patients with chronic myeloid leukemia (CML) refractory to imatinib mesylate. Blood 102, 909a (2003) (Abstract 3382).
87. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol. 310 Suppl. 1), 28-39 (2004).